No connection

Search Results

XAIR vs XTLB

XAIR
Beyond Air, Inc.
BEARISH
Price
$0.55
Market Cap
$5.8M
Sector
Healthcare
AI Confidence
95%
XTLB
XTL Biopharmaceuticals Ltd.
BEARISH
Price
$2.44
Market Cap
$5.8M
Sector
Healthcare
AI Confidence
95%

Valuation

P/E Ratio
XAIR
--
XTLB
--
Forward P/E
XAIR
-0.33
XTLB
--
P/B Ratio
XAIR
0.57
XTLB
--
P/S Ratio
XAIR
0.83
XTLB
5.98
EV/EBITDA
XAIR
-0.69
XTLB
--

Profitability

Gross Margin
XAIR
1.82%
XTLB
-232.85%
Operating Margin
XAIR
-300.64%
XTLB
-853.58%
Profit Margin
XAIR
0.0%
XTLB
0.0%
ROE
XAIR
-240.21%
XTLB
-577.13%
ROA
XAIR
-51.2%
XTLB
-240.56%

Growth

Revenue Growth
XAIR
104.7%
XTLB
--
Earnings Growth
XAIR
--
XTLB
--

Financial Health

Debt/Equity
XAIR
2.85
XTLB
--
Current Ratio
XAIR
5.12
XTLB
0.7
Quick Ratio
XAIR
2.59
XTLB
0.46

Dividends

Dividend Yield
XAIR
--
XTLB
--
Payout Ratio
XAIR
0.0%
XTLB
0.0%

AI Verdict

XAIR BEARISH

XAIR exhibits severe financial distress, anchored by a critical Piotroski F-Score of 1/9 and an operating margin of -300.64%. While the company shows impressive top-line revenue growth (>100% YoY), it is failing to convert this into any meaningful profitability, with gross margins nearly flat at 1.82%. The massive disconnect between the current price ($0.55) and the analyst target price ($8.67) suggests a speculative bubble or outdated analyst models that ignore the company's deteriorating fundamental health. With a 5-year price collapse of 99.5%, the stock is in a clear long-term bearish trend.

Strengths
Strong YoY revenue growth of 104.70%
Strong Q/Q revenue growth of 104.66%
High current ratio (5.12) suggesting short-term liquidity
Risks
Extreme operating inefficiency with -300.64% operating margin
Critical financial health indicated by Piotroski F-Score of 1/9
High leverage with Debt/Equity ratio of 2.85
XTLB BEARISH

XTLB exhibits severe financial distress, anchored by a weak Piotroski F-Score of 3/9 and a complete lack of positive fundamental momentum. The company suffers from catastrophic profitability metrics, including an operating margin of -853.58% and a negative gross margin of -232.85%, indicating a fundamentally broken cost structure. Liquidity is critical with a current ratio of 0.70 and a quick ratio of 0.46, suggesting an inability to meet short-term obligations. Combined with a 0/100 technical trend and an 81.5% decline over five years, the stock presents an extremely high-risk profile.

Strengths
Low current price relative to 52-week high ($10.28)
Positive EPS surprise recorded in historical 2015 data
Micro-cap status allows for high volatility spikes
Risks
Severe liquidity crisis (Current Ratio 0.70)
Extreme negative margins (Operating Margin -853.58%)
Chronic value destruction (5Y Change -81.5%)

Compare Another Pair

XAIR vs XTLB: Head-to-Head Comparison

This page compares Beyond Air, Inc. (XAIR) and XTL Biopharmaceuticals Ltd. (XTLB) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile